Using phosphine ligands with a biological role to modulate reactivity in novel platinum complexes by Echeverri, Marcelo et al.
rsos.royalsocietypublishing.org
Research
Cite this article: Echeverri M, Alvarez-Valdés
A, Navas F, Perles J, Sánchez-Pérez I, Quiroga
AG. 2018 Using phosphine ligands with a
biological role to modulate reactivity in novel
platinum complexes. R. Soc. open sci. 5: 171340.
http://dx.doi.org/10.1098/rsos.171340
Received: 19 September 2017
Accepted: 16 January 2018
Subject Category:
Chemistry
Subject Areas:
inorganic chemistry/medicinal
chemistry/crystallography
Keywords:
metallodrug–protein interaction, cytotoxicity,
platinum drugs and DNA
Author for correspondence:
A. G. Quiroga
e-mail: adoracion.gomez@uam.es
This article has beeneditedby theRoyal Society
of Chemistry, including the commissioning,
peer review process and editorial aspects up to
the point of acceptance.
Electronic supplementary material is available
online at https://dx.doi.org/10.6084/m9.
figshare.c.3992886.
Using phosphine ligands
with a biological role to
modulate reactivity in novel
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3Instituto de Investigaciones Biomédicas Albert Sols, Madrid, Spain
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Three platinum complexes with cis and trans configuration
cis-[Pt(TCEP)2Cl2], cis-[Pt(tmTCEP)2Cl2] and trans-
[Pt(TCEP)2Cl2], where TCEP is tris(2-carboxyethyl)phosphine,
have been synthesized and fully characterized by usual
techniques including single-crystal X-ray diffraction for
trans-[Pt(TCEP)2Cl2] and cis-[Pt(tmTCEP)2Cl2]. Here, we also
report on an esterification process of TCEP, which takes place
in the presence of alcohols, leading to a platinum complex
coordinated to an ester tmTCEP (2-methoxycarbonylethyl
phosphine) ligand. The stability in solution of the three
compounds and their interaction with biological models
such as DNA (pBR322 and calf thymus DNA) and proteins
(lysozyme and RNase) have also been studied.
1. Introduction
The discovery of new metallodrugs that can overcome the
unwanted effects produced by cisplatin [1] (currently the
better known metallodrug in the clinic) or carboplatin has led
to novel platinum complexes with non-conventional design.
Some of those non-conventional examples go against the
cis configuration requirements established by cisplatin [2];
for example, new active species are possible using [trans-
PtX2(L)(L′)] complexes. Metallodrugs such as organometallic
AuIII/RuII/OsII/RhIII/IrIII complexes have emerged as a new
trend in non-conventional metallodrugs due to their potential
activation by the redox balance in cancer cells and/or their protein
interaction [3,4].
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Trans complexes have been studied in detail, revealing that synthetic variations of transplatin in the
coordinating ligands X and L [2,5] conferred cytotoxic activity in particular for cisplatin-resistant cell
lines. Several structural motifs have been explored within these variations including diamine complexes
[6], polyplatinum compounds, photoactivatable azide complexes [7], intercalator-linked species [8,9] and
monofunctional compounds [10]. Among these examples, we are especially interested in aliphatic amine
compounds with phosphines in trans configuration.
The use of these bulky ligands with hydrophobic properties can produce steric impediments and may
be the cause of the increased cytotoxicity. Phosphines are then a good group to design not only catalysts
but also potential metallodrugs. Looking for phosphines with biological properties that could improve
the pharmacokinetics of a platinum complex, we found that tris(2-carboxyethyl)phosphine (TCEP)
is a soluble phosphine, widely used in biochemical systems [11]. Its esterification derivative, tris(2-
methoxycarbonylethyl)phosphine (tmTCEP), showed even higher permeability than TCEP through the
cell membrane [11] and even higher reactivity as a reducing agent. An interesting biological interaction
has been reported for TCEP in the cisplatin–protein adduct formation with Atox1 [12], a chaperon protein
related to copper transport inside the cell. The isolation and X-ray characterization of an adduct with
cisplatin and this protein helped in the understanding of this drug reactivity inside the cell [13].
The use of TCEP as a phosphine-coordinating ligand could improve not only the solubility of
platinum compounds, but also their transport through the cell and even their secondary effects. We have
synthesized, characterized and compared with previous results [14] cis and trans complexes using TCEP
and tmTCEP.
2. Results and discussion
2.1. Chemistry
The reaction of tetrachloroplatinate with TCEP in water leads to the formation of the cis-[Pt(TCEP)2Cl2]
(1) complex (scheme 1). The absence of oxygen is a very important condition for the isolation of the pure
compound; otherwise, the TCEP oxidizes. Monitoring the reaction by 31P-NMR detects a new signal at
15.9 ppm highly shifted from the free ligand signal at 56.7 ppm.
The characterization of complex 1 was performed by the usual techniques and the detailed data are
compiled in the Experimental part. All the techniques indicate that the structural proposal adjusts to the
general formula cis-[Pt(TCEP)2Cl2]; only one signal in the 31P-NMR and 195Pt-NMR spectra at 4.87 and
at −4420.5 ppm, respectively [15], confirmed the PtCl2P2 coordination and the two ν(Pt–Cl) stretching
bands in the IR spectrum at 261 and 361 cm−1 confirm the cis configuration.
Our next step was the esterification of TCEP to get tmTCEP and the corresponding complex. We
found the esterification reported in the literature, and it was carried out in MeOH in the presence of a
cation-exchange resin followed by a preparative HPLC purification [11].
In our method, we have avoided these tedious stages and proceed with both esterification and
platinum complex formation in only one step. The reaction of K2PtCl4 with two equivalents of TCEP
using MeOH as a solvent leads to a quantitative formation of cis-Pt(tmTCEP)2Cl2 (2; scheme 2).
We monitored the reaction by 1H-NMR (figure 1) and observed the beginning of the reaction already
after 10 min, where a new set of signals arises corresponding to the tmTCEP coordinated to the platinum
atom. The final complex 2 is the major species after 24 h. Following the same procedure as with the
previous complexes, we used the usual techniques to characterize complex 2, with all details available
in the Experimental part and the electronic supplementary material.
The characterization by NMR showed clearly the esterification, with a new signal corresponding to
the methoxy group at 3.72 ppm in the 1H-NMR spectrum and at 52 ppm in the 13C-NMR spectrum.195Pt-
NMR, at −4433 ppm, is in agreement with a Pt atom bound to phosphorus and chloride atoms [15]. The
lack of the ν(O–H) stretching band and the ν(C=O) at 1734 cm−1 in the complex 2 IR spectrum support
the esterification of the TCEP ligand. The two ν(Pt–Cl) bands at 283 and 317 cm−1 are in accordance with
a cis configuration (C2 V symmetry).
The stability of the complex solutions in water was analysed for complexes 1, 2 and 3. The cis complex
1 in water solution slowly isomerizes to the trans counterpart 3 (scheme 3). This process takes place
very slowly and it can be accelerated starting with a very concentrated solution and increasing the
temperature (50°C).
We detected no changes for complex 2 and 3 solutions (dimethylsulfoxide (DMSO) and D2O solutions)
when monitoring the solution by 1H-NMR over 24 h. UV–visible spectrophotometric analysis allowed
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Scheme 1. Formation reaction of cis-[Pt(TCEP)2Cl2.
Scheme 2. Formation reaction of cis-[Pt(tmTCEP)2Cl2.
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Figure 1. Progress of the reaction of scheme 2 asmonitored by 1H-NMR spectroscopywith regard to the time: 10 min, 1 h inMeOH solution
and pure complex 2 (at the top).
Scheme 3. Isomerization of complex 1 to complex 3.
the calculation of the constants (table 3) based on the absorption profile plottings as a function of
time (included in electronic supplementary material, figure S1) [16]. The stability of the cis complex
is higher than that of the trans counterpart. This trend is consistent with a more rapid aquation step
for the trans configuration [17]. (K (s−1) values have been compiled with the protein interaction in
table 3.)
Complex 3 was also fully characterized by the usual techniques which allowed one to confirm the
trans-[Pt(TCEP)2Cl2] configuration with only one active ν(Pt–Cl) stretching band in the IR spectrum
at 325 cm−1 expected for a D2 h symmetry group. 31P-NMR and 195Pt-NMR signals at 9.25 and at
−4357.5 ppm [15] showed a clear difference with the trans counterpart.
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Figure 2. Molecular view of the two crystallographically independent molecules found in the structure of complex 3. Hydrogen atoms
have been omitted for clarity.
Table 1. Selected distances and angles for complex 3. Symmetry operations: #1− x,−y + 1,−z + 2; #2−x + 1,−y + 1,−z + 1.
bond distances (Å) bond angles (°)
Pt1–P1 2.311(1) P1–Pt1–P1#2 180 P1–Pt1–Cl1 93.47(5)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt1–Cl1 2.337(1) P1–Pt1–Cl1#2 86.53(5) P1#2–Pt1–Cl1#2 93.47(5)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
P1#2–Pt1–Cl1 86.53(5) Cl1–Pt1–Cl1#2 180
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt2–P2 2.296(1) P2–Pt2–P2#1 180 P2#1–Pt2–Cl2#1 86.57(5)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt2–Cl2 2.336(1) P2–Pt2–Cl2#1 93.42(5) P2#1–Pt2–Cl2 93.43(5)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
P2–Pt2–Cl2 86.58(5) Cl2#1–Pt2–Cl2 180
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2. Structural study
Compounds 2 and 3 were obtained as crystals suitable for single-crystal X-ray diffraction. Unfortunately,
the many attempts performed for the recrystallization of complex 1 did not afford good results, and
we were not able to obtain the X-ray structure of this cis complex, although this compound had
previously been obtained as a solvate ([cis-PtCl2(TCEP)2]·1,25H2O) and its structure had been solved
[14]. Compound 1 might be difficult to obtain as single crystals because of its slow isomerization in
water solution to the trans counterpart, complex 3.
We have carefully compared the crystal structure of complex 3 (figure 2) with the deuterated form
(trans-[PtCl2{P(C2H4COOD)3}2]) described in the literature [14], and found that both are isostructural.
Compound 3 crystallizes in the triclinic P-1 space group with two halves of trans-Pt(tmTCEP)2Cl2
molecules per asymmetric unit. Both Pt1 and Pt2 platinum atoms show a square planar geometry with
the expected angles for this coordination environment. Distances Pt–Cl are slightly longer than those
found in the literature for similar trans compounds, and in the range 2.301–2.317 Å [18,19]; Pt–P distances
are also within the expected range of 2.315–2.373 Å [18,20] (table 1). The supramolecular packing in
the crystal is mainly achieved by double O· · · HO interactions (see electronic supplementary material,
table 1) of the six terminal carboxylic groups with those of neighbouring molecules, giving rise to a very
interesting supramolecular network.
To gain a deeper insight on the potential assembly and organization of this molecule and study
the interactions detected in the supramolecular network, a topological study [21,22] was performed
with TOPOS [23–25] considering the molecules as nodes and the hydrogen bonds as linkers. Each
molecule was found to be connected to six neighbours (one for each carboxylic acid, see electronic
supplementary material, figure S3), giving rise to a uninodal three-dimensional net with pcu topology
(pcu= primitive cubic, figure 3b). There are four independent three-dimensional supramolecular nets,
which are interpenetrated (class Ia, Z= 4) as depicted in figure 3 and electronic supplementary material,
figure S3. This dense three-dimensional web of interactions is responsible for the poorer solubility of
compound 3 in its crystalline form and could affect the availability of this molecule when used as a drug
if dispensed in its crystalline form.
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(b)(a) (c)
Figure 3. (a) Details of the double hydrogen bond between neighbour carboxylic acid groups found in 3. (b) Single underlying pcu
supramolecular three-dimensional net considering these interactions. (c) Resulting fourfold interpenetration of the individual pcu nets.
P2 Cl2
Cl1
Pt1
P1
Figure 4. Molecular structure of complex 2.
The crystal structure of complex 2 was also solved and corroborates all the other characterizations
performed. Figure 4 shows the molecule in the asymmetric unit, with the Pt atom in a square planar
geometry with an angle P1–Pt1–P2 of 104.98°, clearly more distorted from the ideal 90° than the
equivalent angle in 1·1,25H2O. The Pt–Cl and Pt–P distances are within the expected range for this kind
of complex: (2.329–2.377 Å) [26,27] and (2.233–2.271 Å) [26,28]; and are very similar to the ones found in
the reported structure for compound 1·1,25H2O (table 2).
If we compare the supramolecular interactions found in the structures of compounds 1·1,25H2O [14]
and 2 with the ones found in 3, we see that, in compound 2, the packing is only achieved by much
weaker hydrogen bonds. As expected, in compound 1·1,25H2O, the supramolecular arrangement also
entails hydrogen bonds comparable in strength to the ones found in 3. However, in the crystal structure of
1·1,25H2O, the disposition of the carboxylic groups in the molecule and the involvement of the interstitial
water molecules in the supramolecular interactions prevent the formation of a network of hydrogen
bonds similar to the one found in 3, which results in a higher solubility in water.
2.3. Biomolecule interactions with the complexes
To estimate the nature of the supramolecular interaction of complexes 2 and 3 with calf thymus
DNA (CT-DNA), we analysed the changes in the typical absorbance at 260 nm of CT-DNA using
spectrophotometric titrations, varying the concentration of each complex (from 37.5 µM to 87.5 µM) with
constant CT-DNA concentration (6.2 × 10−5 M) (figure 5).
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Figure 5. UV–visible analysis of CT-DNA interaction with increasing concentration of complex 2 (a) and complex 3 (b) in Tris–HCl buffer
solution.
Table 2. Selected distances and angles for complexes 2 and 1·1,25H2O [14].
bond distances (Å) bond angles (°)
2 Pt1–P1 2.254(1) P1–Pt1–P2 104.98(4) P1–Pt1–Cl1 84.68(4)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt1–P2 2.255(1) P2–Pt1–Cl1 170.32(4) P1–Pt1–Cl2 170.93(4)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt1–Cl1 2.365(1) P2–Pt1–Cl2 83.18(4) Cl1–Pt1–Cl2 87.14(4)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt1–Cl2 2.350(1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1·1,25H2O Pt1–P1 2.2597(8) P1–Pt1–P2 96.36(2) P1–Pt1–Cl1 90.48(2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt1–P2 2.2455(8) P2–Pt1–Cl1 173.15(2) P1–Pt1–Cl2 174.62(2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt1–Cl1 2.3714(8) P2–Pt1–Cl2 88.72(2) Cl1–Pt1–Cl2 84.43(2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt1–Cl2 2.3588(8)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt2–P3 2.2539(7) P3–Pt2–P4 95.36(2) P3–Pt2–Cl3 89.84(2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt2–P4 2.2571(8) P4–Pt2–Cl3 174.49(2) P3–Pt2–Cl4 175.81(2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt2–Cl3 2.3616(9) P4–Pt2–Cl4 88.80(2) Cl3–Pt2–Cl4 85.99(2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pt2–Cl4 2.3558(8)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Both complexes showed the same pattern of interaction. Increasing the complex concentration, the
DNA absorption band at 260 nm increases, showing a known effect named hyperchromism. Cisplatin
has been widely reported to produce a bathochromic shift from 260 to 265 nm [29] caused by perturbation
resulting from covalent bonding between the Pt atom and the N7 atoms of the purine bases which
is obviously not observed in complex 1 and 2. Hyperchromism indicates a decrease in the degree of
unwinding, whether produced by covalent binding or by non-covalent interaction [30].
To further support the different interaction of those complexes we also studied their interaction with
the DNA plasmid supercoiled pBR322 (which contains two isoforms). Cisplatin has been reported to
alter both forms of this plasmid to such a degree until they co-migrate at ri = 0.02 (ri = molar ratio
Pt/nucleotide) in an electrophoresis experiment. The CC form (closed circular) is delayed because of
the platination, and the OC form (open circular) slows down because of the unwinding. Complexes 2
and 3 (figure 6) do not produce any changes in the electrophoretic mobility of both forms, demonstrating
that they do not have any binding affinity towards this DNA model.
Hydrodynamic methods such as determination of viscosity are sensitive to the change of length of
DNA that allows one to shed some light on the nature of the interaction with DNA.
Complex 1 reactivity with a dsDNA has been recently studied in the presence of a model lipid
membrane [31]. The results suggested that bonding of complex 1 to DNA leads to a much more compact
structure than cisplatin’s DNA bonding, revealing complex 1 interacts by hydrogen bonding on the
7rsos.royalsocietypublishing.org
R.Soc.opensci.5:171340
................................................
complex 2 complex 3 cisplatin
CC
OC
co
n
tr
ol
0.
01
0.
05 0.
1
0.
2
0.
01
0.
05 0.
1
0.
01
0.
05 0.
1
0.
2
Figure6. Electrophoresis in agarose gel of complex 2 (lines 2–5) and 3 (lines 6–9)with pBR322 at ri = 0.001 to 0.2. Cisplatin (lines 10–12)
and pBR322 control (line 1) have been included for comparative purposes.
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Figure 7. Effect of increasing amounts of compounds 1, 2 and 3 on the viscosity of CT-DNA. The data were collected for
[DNA]= 6.2× 10−5 M at diverse 1/R ratios (R= [DNA]/[compound]).
hydrophilic regions. Based on this information and on the experiments carried out so far with these
complexes, the determination of the viscosity produced by the complexes becomes an interesting tool
to study the nature of their interaction with DNA. Specifically, the relationship between the relative
viscosity and the contour length is of the form L/L0 = (η/η0)1/3, where L0 and η0 denote the apparent
DNA molecular length and the solution viscosity, respectively, in the absence of a tested compound.
A classical intercalator molecule like ethidium bromide causes a significant increase in the viscosity
of the DNA solution due to the separation of base pairs at the interaction site and an increase in overall
double helix length, whereas a groove binder agent like Hoechst 33258 does not appreciably lengthen the
DNA helix and, therefore, causes less-pronounced changes or no changes at all in the viscosity of DNA
solutions. A covalent binder case, for example cisplatin, causes a decrease in the relative viscosity of the
DNA solution [32]. The values of cube root of the relative specific viscosity, (η/η0)1/3, versus the ratio of
the complex concentration to DNA, 1/R (where R= [CT-DNA]/[compound]), in the absence and in the
presence of compounds 1, 2 and 3 are plotted in figure 7.
The three compounds exhibit no changes in the viscosity, indicative of non-covalent interaction
(as the example described for Hoechst), which is also in agreement with the spectrophotometric
studies performed with CT-DNA. Compound 2’s structure does not show the same bonding site (the
carboxyethyl group has been methylated), so the electrostatic interaction can be discarded and only
hydrogen bonding can be possible, though much weakened.
The importance of TCEP as a reductor in biological systems, its significant role in the cisplatin
crystallization with Atox1 and the fact that complex 3 reacts with glutathione in water to afford species
prompted us to compare such interaction with protein models using both complexes 2 and 3.
The selected models are: (i) egg white lysozyme (HEWL, hen egg white lysozyme), which is a protein
broadly used as a model for interaction of metallodrugs [33] and (ii) bovine pancreatic RNase, often
used as a model also for complex interaction with a ribonucleotide reductase enzyme [34]. In table 3,
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Figure 8. Survival of MKN45 and ST2957 cells after treatment with CDDP or new complexes 2 and 3. (a) MKN45 and (b) ST2957 cell
lines were treated with increasing amounts of CDDP (open circles), complex 2 (filled squares,µM) or complex 3 (open squares). Viability
was quantified using the crystal violet method 72 h after treatment. The percentage is shown as relative to the number of cells without
treatment. Data represent the means of two experiments performed in quadruplicate.
Table 3. Calculated values for: stability K, interaction with HEWL (KHEWL) and RNase (KRNase) of complexes 2, 3 and cisplatin.
complex K (s−1) KHEWL (s−1) KRNase (s−1)
2 5.98× 10−5 1.90× 10−4 1.55× 10−4
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 1.12× 10−4 1.38× 10−4 5.50× 10−4
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
cisplatin 4.45× 10−5 [35] 1.98× 10−4 1.88× 10−4
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4. IC50 values (µM) for complexes 2, 3 and cisplatin.
cell line cisplatin (µM) complex 2 (µM) complex 3 (µM)
MKN45 7 132 50
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ST2957 20 >150 73
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
we have also compiled the KHEWL and KRNase data, calculated based on a pseudo first-order reaction of
complexes 2 and 3 with the protein models. (All the data have been compiled and presented in detail in
the Experimental section and electronic supplementary material, figures S4–S6.)
The constant values of interactions with both proteins for complexes 2 and 3 are very similar and also
consistent with the stability values. In spite of the similarity, we can see that complex 3 (trans isomer)
shows a slightly higher affinity for RNase.
2.4. Cytotoxicity
Cisplatin derivatives are widely used in the treatment of gastric cancer disease. To investigate the
effect of these compounds in vitro, we studied the survival of the two most common human gastric
adenocarcinoma cell lines (MKN45 and ST2957) after treatment with increased doses of each compound
and compared with cisplatin. We analysed cell survival 72 h after treatment with cisplatin (0–150 µM),
compound 2 (0–150 µM) or compound 3 (0–100 µM). Our results indicated that as we have previously
described, both cell lines MKN45 and ST2957 showed cisplatin sensitivity with different IC50: 7 versus
20 µM, respectively [36].
Compound 2 has no effect on viability in either MKN45 or ST2957 cell lines. By contrast, compound
3 decreased survival on both cell lines in a dose-dependent manner reaching IC50 of 50 µM for MKN45
cells versus 73 µM for ST2957 cells. These results suggest that compound 3 has a biological effect on
gastric cancer cells (figure 8). Table 4 shows the IC50 required for each compound. Our data indicate that
complex 3 needs a much higher dose than cisplatin to kill tumour cells. However, the dose used is in the
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same range as that of carboplatin used to kill these cells. Furthermore, carboplatin is an approved clinical
drug in use, so our results could represent a step forwards in new drug design.
According to the values of table 4, we think that the viability data cannot be only produced by a
DNA lesion, but also other molecular targets might be involved. These results are of high importance
to overcome the problems with cisplatin treatment and its secondary side effects, and have opened up a
new field of investigation that must extend the knowledge of its mechanism of action not only through
apoptosis but also through new cell routes described for these particular cancer cells [37].
3. Experimental
3.1. Material and methods
Monodimensional 195Pt-NMR, 13C-NMR and 1H-NMR experiments were performed in DMSO-d6 and
D2O using a Bruker AMX-300 (300 MHz) spectrometer at room temperature (25°C). Elemental analyses
were performed with a PerkinElmer 2400 Series II microanalyzer. IR was performed with a PerkinElmer
Model 283 spectrophotometer with an ATR accessory (Miracle Single Reflection Horizontal). UV–visible
spectroscopy was performed with a Thermo Fisher Scientific Evolution 260 Bio spectrophotometer. Mass
spectrometry was performed with a QSTAR de ABSciex by electrospray.
3.2. Single-crystal X-ray diffraction
X-ray diffraction data collection was done at 296(2) K for compounds 2 and 3 with a Bruker Kappa Apex
II diffractometer using graphite-monochromated Mo-Kα radiation (λ= 0.71073 Å). Details on the data
collection and refinement are gathered in electronic supplementary material, tables S2 and S3. CCDC
1519230 and 1519231 contain the supplementary crystallographic data for compounds 2 and 3. The data
can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.
uk/structures.
3.3. Cytotoxicity assay
Viability was determined using a crystal violet-based staining method, as described previously [38].
Briefly, 5 × 104 cells per well were seeded in 24 multiwell dishes, treated with cisplatin (0–150 µM)
complex 2 (0–150 µM) or complex 3 (0–100 µM) for 72 h and fixed with 1% glutaraldehyde. After they
were washed in 1× phosphate-buffered saline, the remaining cells were stained with 0.1% crystal violet.
Colorimetric assay using 595 nm Elisa was used to estimate the number of cells per well. Complexes 2
and 3 were dissolved in water. IC50 values were calculated by using the GraphPad Prism program. We
used nonlinear regression to fit the data to the log (inhibitor) versus response (variable slope) curve.
3.4. Synthetic procedures
3.4.1. Synthesis of cis-[Pt(TCEP)2Cl2], complex 1
A 4 ml aliquot of a degassed water solution containing 37.2 mg of K2PtCl4 was added to 50.2 mg of TCEP
previously dissolved in 2 ml of H2O. The addition was performed under an argon atmosphere and the
reaction was stirred at room temperature for 24 h. The final white solid was filtered off and washed with
cold water, 766.36 g mol−1. Yield: 73.9%. Calculated analysis for C18H30Cl2O12P2Pt: 28.21% C; 3.95% H;
0% H; Found: 27.81% C; 3.92% H; 0% N. 1H-NMR (DMSO, 300 MHz) δ 2.30 (H1, 12 H), δ 2.55 (H2, 12
H). 13C-NMR (DMSO, 300 MHz) δ 19.0 (C1), δ 28.7 (C2), δ 172.7 (C3). 31P-NMR (DMSO, 300 MHz) δ 4.18
(s, 1JPPt = 3482.9). 195Pt-NMR (DMSO, 300 MHz) δ −4420.5 (t, 1JPtP = 3486.36) MHz) δ 19.0 (C1), δ 28.7
(C2), δ 172.7 (C3). 31P-NMR (DMSO, 300 MHz) δ 4.18 (s, 1JPPt = 3482.9). 195Pt-NMR (DMSO, 300 MHz)
δ −4420.5 (t, 1JPtP = 3486.36). Anal. (%) calcd. for C18H30Cl2O12P2Pt. C: 28.21, H: 3.95, N: 0. Found. C:
27.81, H: 3.92, N: 0. ESI-MS [M–Cl]+: m/z 731.
3.4.2. Synthesis of cis-[Pt(tmTCEP)2Cl2], complex 2
TCEP (49.8 mg) previously dissolved in 2 ml of MeOH was added to a suspension of 36.5 mg of K2PtCl4
in methanol under an argon atmosphere. The mixture was stirred at room temperature for 2 days.
The final white solid was filtered and washed with water and methanol. 850.52 g mol−1. Yield: 73.9%.
1H-NMR (CD3OD, 300 MHz) δ 2.44 (H1, dt, J= 7.2 y 3.2 Hz, 12 H), δ 2.76 (H2, dt, J= 7.2 y 1.8 Hz, 12 H),
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δ 3.30 (H4, s, 18 H); 13C-NMR (CD3OD, 300 MHz) δ 20.81 (C1). δ 29.90 (C2). δ 52.68 (C4). δ 174.0 (C3);
31P-NMR (CD3OD, 300 MHz) δ 4.87 ppm (s, 1JPPt = 3525.24). 195Pt-NMR (CD3OD, 300 MHz) δ
−4433.08 ppm (t, 1JPtP = 3522.15). Anal. (%) calcd. for C24H42Cl2O12P2Pt. C: 33.89, H: 4.98, N: 0. Found.
C: 33.83, H: 4.82, N: 0. ESI-MS [M–Cl]+: m/z 815.14.
3.4.3. Synthesis of trans-[Pt(TCEP)2Cl2], complex 3
Cis-[Pt(TCEP)2Cl2], 2 (20 mg) was heated in 5 ml of D2O, at 100°C for 20 min. Lowering the temperature
of the final solution to room temperature gave the full precipitation of a yellow solid. The solid was
isolated by filtration and washed with cold water and dried in a drying oven. 766.36 g mol−1. Yield: 92%.
1H-NMR (D2O, 300 MHz) δ 2.35 (H1, 12 H), δ 2.83 (H2, 12 H) 12.3 ppm (O–H, broad, 6H and interchange
with D2O); 13C-NMR (D2O, 300 MHz) δ 16.2 (C1), δ 28.5 (C2), δ 172.7 (C3); 31P-NMR (D2O, 300 MHz) δ
9.25; 195Pt-NMR (D2O, 300 MHz) δ −4357.51. Anal. (%) calcd. for C18H30Cl2O12P2Pt. C: 28.21, H: 3.95,
N: 0. Found. C: 28.63, H: 3.78, N: 0. ESI-MS [M+Na]+ : m/z 788.99.
3.5. Sample preparation for interaction with model proteins
To evaluate the biological behaviour of complexes 2 and 3, they were initially dissolved in DMSO in
a 5 mM concentration. For all experiments, the desired concentration of complexes was achieved by
dilution of the stock DMSO solution with aqueous buffer. Cisplatin stock solutions were prepared in
5 mM NaClO4 and diluted in Milli-Q water. All the solutions and buffers were previously tempered to
37°C. Afterwards, the freshly prepared complex solutions were mixed in a thermoshaker at 37°C with
Milli-Q water (for stability K) [16] and aqueous buffer Tris (for DNA/model protein solutions). The
studies never exceeded 0.5% DMSO (v/v) in the final solution. Control experiments with DMSO were
performed and no changes in the spectra of the model proteins or CT-DNA were observed.
3.6. Complexes and CT-DNA interaction
Binding experiments of complexes 2 and 3 to CT-DNA were analysed twice by spectrophotometric
titrations, keeping constant the CT-DNA concentration (6.2 × 10−5 M) while varying the concentration
of each complex (0–87.5 µM) and monitoring the changes in the typical absorbance of CT-DNA at 260 nm
after equilibration (10 min, at 37°C).
3.7. Viscosity studies
The viscosity experiments were carried out in automated AND viscometer model SV-1A, at constant
temperature of 25.0 ± 0.1°C using a water bath with thermostat control. The concentration of CT-
DNA was maintained constant (6.2 × 10−5 M), with increasing concentrations of complexes 1, 2 and 3
(0–87.5 µM) to ratios in the range of 0–8.8 (1/R= [compound]/[CT-DNA]). Complexes 2 and 3 were
initially dissolved in DMSO : water at a 5 mM concentration. The dilution was performed using Tris–HCl
buffer to a final volume of 2 ml containing a maximum amount of 1.0% of DMSO.
Viscosity experiments were recorded twice, taking two different measurements for each experiment
(time 0 and 10 min).
3.8. pBR322 interaction with the complexes
The DNA-binding studies were performed in a total volume of 20 µl. The DNA aliquots containing 8 ml
of DNA-pBR322 (10 ng ml−1 stock) in 10 mM Tris–HCl (pH 7.6) and 1 mM EDTA were incubated with the
platinum compounds at several ri values (0.01–0.5) using the corresponding amount of platinum from
either a 5 or 50 µM stock solution. (Stock solutions were prepared in water and used fresh.) The samples
were incubated at 37°C for 24 h, after which time 2 µl of a loading dye containing 50% glycerol, 0.25%
bromophenol blue and 0.25% xylene cyanol was added. The whole of the sample (20 µl) was loaded in
the wells of a 0.8% agarose gel. Electrophoresis was carried out for a period of 2.5 h at approximately 50 V.
After electrophoresis, the gel was immersed in 800 ml of Millipore water containing 64 µl of a 10 mg ml−1
stock solution of ethidium bromide for 30 min to stain the DNA.
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3.9. UV–visible kinetics experiments with protein
To investigate the interaction of cisplatin and complexes 2 and 3 with plasma proteins, electronic spectra
of the protein models HEWL and RNase A at 10−5 M were recorded before and after the addition of
complexes 2 and 3 for 24 h and at 37°C, and at a stoichiometric ratio of 10 : 1 and 3 : 1 (metal to protein)
with the same results. The experimental time-dependent spectral profile was analysed as a pseudo first-
order reaction by plotting the variation of the absorbance as a function of time (absorption profiles
in electronic supplementary material, figures S4–S6, and plots in electronic supplementary material,
figure S6).
4. Conclusion
We report the synthesis of three platinum complexes using TCEP and tmTCEP (where esterification
and coordination take place in the same step). The crystal structures demonstrated cis configuration for
complex 2 and trans for complex 3. A comparative study of the supramolecular interactions in the solid
state has been performed. The cis complex 1 affords slow isomerization to complex 3 in water solution,
while complexes 2 and 3 showed good stability in water solution and Tris–HCl buffer. The reactivity
of these two stable compounds is higher when they interact with model proteins than with DNA. The
complexes do not react when they face the secondary DNA structure model (pBR322), and with CT-DNA
they act very differently compared with cisplatin.
Data accessibility. The crystallographic data can be obtained free of charge from the Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/structures; CCDC 1519230 and 1519231 contain the supplementary crystallographic
data for compounds 2 and 3. Data for the paper and cif data are in the electronic supplementary material.
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